Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
initial public offering
Biotech
Alopexx seeks IPO to advance ex-Sanofi infectious disease drug
Alopexx updated IPO paperwork to fund trials of candidates including an antibody that was once the focus of a $375 million deal with Sanofi.
Nick Paul Taylor
Feb 26, 2025 10:04am
Tempus AI IPO drives $6.6B in VC exit value for medtech sector
Aug 21, 2024 10:21am
Rapport talks up $122M IPO for proof-of-concept epilepsy trials
Jun 3, 2024 7:10am
A closer look at European biotech investment in 2024
Mar 22, 2024 8:43am
Kyverna raises IPO expectations to almost $300M
Feb 6, 2024 9:46am
Gene editing biotech Metagenomi plans modest $87M IPO
Feb 5, 2024 9:14am
